Prostaglandins and Cancer. Eds. T.J. Powles, R.S. Bockman, K.V. Honn, P. Ramwell. Publishers, Alan Liss Inc., New York, l982.
Breast Cancer Management. Eds. R.C. Coombes, T.J. Powles, H.T. Ford, J.C. Gazet. Publishers, Academic Press Inc. (London) Ltd. l98l.
Bone Metastases: new perspectives in the management of advanced breast cancer. Ed T J Powles. Publishers Mediq Ltd, London. 1991.
Medical management of breast cancer. Eds TJ Powles, IE Smith. Publishers Martin Dunitz, London 1991.
Breast cancer: Sharing the decision. Eds. AM Maslin, TJ Powles. Publishers Oxford UniversityPress, England 1999.
Papers, Chapters, Letters
Powles TJ, Easty GC, Easty DM, Bondy, PK, Neville A.M.
Powles TJ, Dowsett M, Easty DM, Easty GC, Neville AM
Aspirin inhibition of in vitro osteolysis stimulated by Parathyroid
Breast cancer osteolysis, bone metastases and anti-osteolytic
effect of aspirin Lancet l, 6O8-6lO (l976).
Powles TJ, Clarke M, Easty DM, Easty GC, and Neville AM
Dowsett M, Easty GC, Powles TJ, Easty DM, and Neville AM
Inhibition by aspirin and indomethacin of osteolytic tumour
Human breast tumour induced osteolysis and prostaglandins.
deposits and hypercalcaemia in rats with Walker tumour and its
possible application to human breast cancer. Br J Cancer 28:
Dowsett M, Eastman AR, Easty DM, Easty GC, Powles TJ and
Neville AM. Prostaglandin mediation of collagenase-induced
Powles TJ, Easty GC, Easty DM, Neville AM (letter)
bone resorption Nature 263, 72-74 (l976).
Antimetastatic effect of aspirin Lancet l, lOO (l973).
Dowsett M, Gazet J-C, Powles TJ, Easty GC, and Neville AM
Powles TJ, Easty DM, Easty GC, Neville AM (letter)
Benign breast lesions and osteolysisLancet l, 97O-97l (l976).
Tumour induced osteolysis Lancet ll, 5O4 (l973).
Powles TJ, Rosset G, Leese CL, and Bondy PK
Powles TJ, Easty DM, Easty GC, Neville AM (letter)
Early morning hydroxyproline excretion in patients with breast
Tumour induced osteolysis New Eng J Med 29l, lO5 (l974).
Easty GC, Powles TJ, Easty DM, Dowsett M, and Neville AM
Antiemetics, prolactin and breast cancer (letter)
The detection of osteolytic substances produced by human breast
tumours IN Organ Culture in Biomedical Research. Ed. Balls and Monnickendam., Pubs. Cambridge University Press p.367-377
Powles TJ, Leese CL, and Bondy PK Hydroxyproline excretion in patients with breast cancer and
response to treatment Br Med J l, l64-l66 (l975).
Smith IE, Taylor KJW, McCready VR, Powles, TJ, and Bondy PK A comparison of grey-scale ultrasound with other methods for
the detection of liver metastases from breast carcinoma Clinical
Mithramycin for hypercalcaemia associated with myeloma and other malignancies Br Med J l: 268 (l975).
Coombes RC, Neville AM, Bondy PK, and Powles TJ
Failure of Indomethacin to reduce hydroxyproline excretion of
Powles TJ, Easty GC, Easty DM, Dowsett M and Neville AM
hypercalcemia in patients with breast cancer Prostaglandins l2,
Some Studies on the Anti-Metastatic Effect of Aspirin. IN
Proceedings of Aspirin Symposium (l975) pp 31-33. Pub. Rayleigh Printers, Essex Ed Dale TLC.
Powles TJ, Easty GC, Easty DM, Dowsett M, and Neville AM
Factors influencing metastasis in bone IN Secondary Spread in
Factors influencing development of bone metastases. IN Cancer
Breast Cancer p8l-93. Heinemann Publishers, Ed. Basil A. Stoll
Invasion and Metastases: Biologic Mechanisms and Therapy Ed.
S.B. Davy, Raven Press, N.Y. pp.425-429 (l977).
Coombes RC, Powles TJ, Gazet JC, Ford HT, Sloane JP, Laurence
Mechanisms for the development of bone metastases and
hypercalcaemia in patients with breast cancer Proc Roy Soc Med
Biochemical Markers in Human Breast Cancer Lancet l, l32-l34
Fatal irreversible hypercalcaemia in breast cancer Br Med J l, l45
Evaluation of biochemical markers in breast cancer Proc Roy Soc
Dady PJ, Gazet J-C, Ford HT, and Powles TJ
Combination chemotherapy for thrombocytopenia with bone
Chemotherapy in breast cancer South West Regional Cancer
marrow metastases from breast cancer Br Med J l, 554-555
Coombes RC, Powles TJ, Gazet J-C, Ford HT, Nash AG, Sloane JP,
Surgical management of breast cancer IN Carcinoma of the
Thomas P, Keyser JW, Marcus D, Stimson W, Neville AM
Breast, Ed. Joslin CA MCS Publications, p.7-l3 (l978).
A biochemical approach to the staging of human breast cancer
Multimodal therapy for Stage II breast cancer (letter) Lancet, l,
Easty GC, Dowsett M, Powles TJ, Easty GC, Gazet J-C, Neville
AM Hypercalcaemia in malignant disease. Proc Roy Soc Med,
Endocrine therapy IN Oncology for Nurses and Health Care
Professionals. Ed. R. Tiffany, Publishers, George Allan & Unwin,
Calcium metabolism in breast cancer. Proc Roy Soc Med 7O,
Smith IE, McKinna JA, Nash AG, Neville AM, Gazet J-C, Ford HT,
Powles TJ, Coombes RC, Neville AM, Ford HT, Gazet J-C, Levine L
l5-keto-l3, l4-dihydroprostaglandin E2 concentrations in serum of
Aminoglutethimide in treatment of metastatic breast carcinoma.
patients with breast cancer Lancet ll, l38, (l977).
Russell JA, Baker JW, Dady PJ, Ford HT, Gazet J-C, McKinna JA,
Russell JA, Baker JW, Dady PJ, Ford HT, Gazet J-C, McKinna JA,
Response of metastatic breast cancer to combination
Combination chemotherapy of metastatic breast cancer with
chemotherapy according to site Br Med J ll: l39O-l39l (l977).
Vincristine, Adriamycin and Prednisolone Cancer 4l, 396-399
Prostaglandins and Breast Cancer IN Tumour Markers, ed. K
Meirion Thomas J, Fitzharris BM, Redding WH, Williams JE, Trott
Griffiths, AM Neville and CG Pierrepoint, p.29l-297 (l977) Pub
Alphas Omega Publishing Company Limited, Cardiff.
Clinical examination, xeromammography and fine needle
aspiration cytology in diagnosis of breast tumours Br Med J 2,
Coombes RC, Neville AM, and Powles TJ The effects of calcitonin, mithramycin and indomethacin in breast
cancer. IN Bone Disease and Calcitonin. Ed. John A. Kains, Pub.
Meirion Thomas J, Redding WH, Coombes RC, Sloane JP, Ford HT,
Armour Company Limited, p.lO3-llO (l977).
Gazet J-C, Powles TJ Failure to detect intra-abdominal metastases from breast cancer:
a case for staging laparotomy Br Med J ll, l57-l59 (l978).
Smith IE, Hedley DW, Powles TJ, McElwain TJ Vindesine
A phase II study in the treatment of breast cancer, malignant
Prostaglandins and Human Breast Cancer Prostaglandins and
melanoma and other tumours Cancer Treatment Reports 62,
Non-steroidal anti-inflammatory drugs and cytotoxics Cancer
Chemotherapy in advanced disease IN Carcinoma of the Breast.
Treatment Reviews (Suppl) 6, 63- 67 (l979).
Ed. CA Joslin MCS Publications, p.4l-46, (l978).
Interactions des substances antimitotiques et anti-inflammatoires
Enhancement of anti-cancer activity of cytotoxic chemotherapy
dans les tissus normaux et neoplasiques IN Colloque Europeen
with protection of normal tissues by inhibition of PG synthesis.
sur le mode d’action des anti-inflammatoires non-steroidiens
Journal of Biochem Pharmacol 27, l389-l392 (l978).
p.lO9-llO (l979). Pubs. Lab. Boot Dacour. Ed. S.S. Adams et al.
Aminoglutethimide in breast cancer Lancet (Letter) 2, ll49 (l978).
Prostaglandines et Osteolyse IN Colloque Europeen sur le mode
d’action des anti-inflammatoires non steroidiens p95-96 (l979)
Pubs. Lab Boot Dacour. Ed. S.S. Adams et al.
Redding WH, Thomas JM, Powles TJ, Ford HT, Gazet J-C Age and prognosis in breast cancer Br Med J, l, l465 (l979).
Smith IE, Hedley DW, Powles TJ, McElwain TJ
Clinical experience with Vindesine in 6O patients with solid
Van Oosterom AT, Powles TJ, Hamersma E, Smith IE and
tumours IN Vindesine Ed RN Wild, Publishers Creative Packaging,
Eli Lilly & Co Ltd Basingstoke ppll-l6 (l979).
A Phase ll study of Mitomycin C in refractory advanced breast cancer. A multi centre pilot sTudy IN Breast Cancer - Experimental
and Clinical Aspects. Proc. 2nd EORTC Breast Cancer Conference,
Coombes RC, Dady PJ, Parsons C, Powles TJ
Copenhagen, l979. Ed ET Mouridsen & T Palshof, Copenhagen,
Mithramycin Therapy: An adjunct to conventional treatment of
Pubs. Pergamon Press pp 275-277 (l979).
hypercalcaemia and bone metastases in breast cancer. Metab.
Bone Dis and Rel Res. 2, l99-2O2 (l98O).
Coombes RC, Neville AM, Gazet J-C, Ford HT, Nash AG, Baker
Smith IE, Hedley DW, Coombes RC, Powles TJ
Agents affecting osteolysis in patients with breast cancer Cancer
A comparison of combination chemotherapy using vindesine or
Chemo & Pharmacol lll, 4l-44, (l979).
vincristine with adriamycin in the treatment of advanced breast
carcinoma Cancer Treatment Reviews 7 7l-73 (l98O).
Premarin in the management of metastatic breast carcinoma in
Powles TJ, Coombes RC, Smith IE, Jones JM, Ford HT,
post menopausal patients Clinical Oncology 5, l59-l62 (l979).
Failure of chemotherapy to prolong survival in a group of patients
with metastatic breast cancer Lancet l,58O-582 (l98O).
Smith IE, and Powles TJ Vindesine in the treatment of breast cancer Cancer Chemotherapy
Bailey MJ, Royce C, Sloane JP, Ford HT, Powles TJ, Gazet J-C
Bilateral carcinoma of the breast. Br J Surg 67, 5l4-5l6 (l98O).
Coombes RC, Powles TJ, Gehrke CW, Waalkes TP, Neville AM
Nucleoside excretion in breast cancer: Comparison with other
Dady PJ, Coombes RC, Smith IE, Parsons CA, Ford HT, Gazet J-C,
biochemical tumour-indexe substances Investigative and Cell
Use of an anti-osteolytic agent in treatment of patients with bone
metastases from breast cancer. IN Breast Cancer - Experimental
and Clinical Aspects. Eds HT Mouridsen and T Palshof Pergamon
Prostaglandins and Cancer Cancer Topics ll,6-7 (l979).
Anti-inflammatory drugs and tumour growth Lancet (l979);
Smith IE, Coombes RC, Ford HT, Gazet J-C, Harmer C, Jones M,
Coombes RC, Powles TJ, Gazet JC, Ford HT, McKinna A, Nash AG,
Aminoglutethimide in the management of advanced breast cancer
Assessment of biochemical tests to screen for metastases in
IN Breast Cancer - Experimental and Clinical Aspects Eds HT
patients with breast cancer Lancet l, 296-298 (l98O).
Mouridsen and T.Palshof Pergamon Press, pp.99-lOl (l98O).
Coombes RC, Powles TJ, Abbott M, De Rivas L, Ford HT,
Smith IE, Coombes RC, Evans BD, Ford HT, Gazet J-C, Gordon C,
McCready VR, Neville AM, Gazet J-C Physical tests for distant
metastases in patients with breast cancer Proc Roy Soc Med.
Vindesine as a single agent and in combination with adriamycin
in the treatment of metastatic breast carcinoma. IN Breast Cancer
- Experimental and Clinical Aspects. Eds. Mouridsen and Palshof.
Grudzinskas JG, Coombes RC, Ratcliffe JG, Gordon YB, Powles TJ,
Circulating levels of pregnancy specific B1 glycoprotein in patients
Coombes RC, Powles TJ, Ford HT, Gazet J-C, Gherke CW, Keyser
with testicular, bronchogenic and breast carcinomas Cancer 45,
JW, Mitchell PEG, Patel S, Stimson WH, Tsou KC, Worwood M,
The value of sequential marker estimations following mastectomy
for breast cancer. IN Breast Cancer - Experimental and clinical
Chemotherapy and Survival in Breast Cancer (Letter) Lancet l,
aspects. Eds. Mouridsen and Palshof. Pergamon Press Ltd., Oxford
de Rivas L, Coombes RC, McCready VR, Gazet JC, Ford HT, Neville
Powles TJ, Dady PJ, Williams J, Easty GC, Coombes RC
Use of inhibitors of prostaglandin synthesis in patients with breast
Tests for liver metastases in breast cancer: evaluation of liver scan
cancer Advances in Prostaglandin and Thromboxane Research,
and liver ultrasound. Clinical Oncology 6, 225-230 (1980).
Coombes RC, Abbott M, Dearnaley DP, Moshakis V, Powles TJ,
Interactions of cytotoxic and anti-inflammatory agents on
Carcinoembryonic antigen estimations as an aid to the
normal and neoplastic tissue. Advances in Prostaglandin and
management of breast cancer. IN Proceedings CEA Und Andere
Thromboxane Research, 6, 587-589 (l98O).
Tumormarker, Ein Symposiumsband, 1980 - Tumor Diagnostic,
Coombes RC, Dearnaley D, Humphreys J, Gazet J-C, Ford HT, Nash
Coombes RC, Jarman M, Harland S, Ratcliffe WA, Powles
Danazol treatment of advanced breast cancer Cancer Treatment
TJ, Taylor GN, O’Hare M, Nice E, Foster AB and Neville AM
Aminoglutethimide: metabolism and effects on steroid synthesis
in vivo. J Endocrinol 87, 3l (l98O).
Prostaglandins and metastases IN Metastatic Tumour Growth Ed E
Dearnaley DP, Patel S, Powles T and Coombes RC
Grundmann Publishers Gustav Fischer Verlag, Stuttgart, New York
Carcinoembryonic antigen estimation in cerebrospinal fluid in
patients with metastatic breast cancer Oncodevelopmental Biology
PG Synthetase Inhibitors in patients with cancer IN Prostaglandin
Synthetase Inhibitors: New Clinical Applications Publishers Alan R
Adjuvant Therapy in Breast Cancer IN Breast Cancer Management.
Liss, Inc, New York pp l83-l86 (l98O).
Ed RC Coombes, TJ Powles, HT Ford, JC Gazet Pubs. Academic
Press Inc. London Ltd (l98l) pp 137-152.
Powles TJ, Gazet JC, Ford HT, Milan J, Dady PJ and Coombes RC
Early detection and monitoring of secondary bone tumours
Dady PJ, Powles TJ, Dowsett M, Easty G, Williams J, Neville AM
IN Bone and Tumours Symposium CEMO lll, Basel, November
In vitro osteolytic activity of human breast carcinoma tissue and
l979 Eds A Donath and B Courvoisier Publishers L’Imprimerie
prognosis Br J Cancer 43, 222-225 (l98l).
Medecine et Hygiene, Geneve, pplO5-lO8 (l98O).
Moon T, Jones S, Davis S, Bonadonna G, Valagussa P, Veronesi U,
Tumour Markers in the management of human cancer IN Topical
Reviews in Radiotherapy and Oncology Ed TJ Deeley, Pubs. John
Development of a natural history data base for breast cancer. In
Wright & Son Ltd, Bristol (l98l) pp 39 - 65.
Adjuvant Therapy of Cancer III Eds Jones & Salmon Pub: Grune &
Endocrine therapy and cancer. IN Cancer Treatment. Ed KE
Halnan, Publishers Chapman and Hall, London pplO3-ll8 (l98l).
Flurbiprofen, a non-steroidal anti-inflammatory agent, protects
cells against hypoxic cell radiosensitizers in vitro. Br J Cancer, 44
Harris AL, Smith IE, Dowsett M, Jeffcote SJ, Coombes RC, Powles TJ, Neville AM
Sex hormone binding globulin levels and prognosis in early breast
Dearnaley DP, Sloane JP, Ormerod MG, Steele K, Coombes RC,
cancer Letter Lancet l, 82l4: 279 (l98l).
Clink H, Powles TJ, Ford HT, Gazet J-C, Neville AM
Increased detection of mammary carcinoma cells in marrow
smears using anti-sera to epithelial membrane antigen. Br J
Coombes RC, Powles TJ, Gazet J-C, Ford HT, McKinna A, Abbott
M, Gehrke CW, Keyser JW, Mitchell PEG, Patel S, Stimson WH, Worwood M, Jones J, Neville AM
Screening for metastases in breast cancer: An assessment of
biochemical and physical methods Cancer 48, 3lO-3l5 (l98l).
Mechanisms of action of DanazolCancer Chemotherapy &
Endocrine therapy of breast cancer IN Breast Cancer Management
Smith IE, Powles TJ, Coombes RC, Ford HT, Gazet J-C, Harmer CL
Ed RC Coombes TJ Powles, HT Ford, J-C Gazet Pubs Academic
A control randomised trial comparing vindesine and adriamycin
with vincristine and adriamycin in the treatment of advanced
breast carcinoma. IN Contributions to Oncology. Eds. W. Brade,
Jones S, Moon T, Davis S, Valagussa P, Bonadonna G, Powles T,
G.A. Nagel, S. Seeber 6, l85-l87 (l98l).
Rivkin S Comparative analysis of selected breast cancer adjuvant trials
in relation to the natural history data base (NHDB) IN Adjuvant
Taylor RE, Powles TJ, Humphreys J, Bettelheim R, Dowsett M,
Therapy of Cancer lll Eds Jones & Salmon, Pubs Grune & Stratton
Effects of Endocrine Therapy on Steroid-Receptor Content of
Breast Cancer Br J Cancer 45,8O (l982).
Survival of patients with metastatic breast cancer treated with
Rowland-Payne, C, Abbott M, Jones JM, Powles TJ, Coombes RC
aminoglutethimide compared to patients treated with cytotoxic
Weight loss during therapy for advanced breast cancer. Clinical
chemotherapy. IN Aminoglutethimide. Mechanism of action and
clinical results in breast cancer. Ed. FJA Paesi, pp.95-98 (l98l).
Powles TJ, Coombes RC, Depledge M, Muindi J, Powles
RL Prostaglandin Administration to patients with cancer IN
Adjuvant Endocrine Therapy. IN Adjuvant Therapy of Cancer III.
Prostaglandins and Cancer Eds Powles TJ, Buckman RS, Honn
Eds. Jones & Salmon. Pubs. Grune & Stratton. p.305-311(l98l).
KV, Ramwell P Pubs Liss, New York pp 825-830 (1982) pp
Adjuvant therapy for primary breast cancer. Editorial Clinical
Heckford Susan E, Eccles Suzanne A, Powles TJ and Alexander P.
Failure of Flurbiprofen to enhance the therapeutic effect of
cyclophosphamide Br J Cancer 46(l): 5l-57 (l982).
Adjuvant therapy of breast cancer IN Breast Cancer Ed M Baum.
Publishers: Update Publications Limited p 20-23 (l98l).
Mechanisms for development of bone metastases and effects of anti-inflammatory drugs. IN Prostaglandins and Cancer: Ed Powles TJ, Buckman RS, Honn KV, Ramwell P Pubs Alan R Liss Inc, NY pp 54l-553 (l982).
Coombes RC, Dearnaley DP, Buckman R, Jones JM, Ormerod MG,
Clinical trial of multiple endocrine therapy for metastatic and
Sloane JP, Powles TJ, Gazet JC, Ford HT, Neville AM
locally advanced breast cancer with Tamoxifen-Aminoglutethimide-
Detection of bone metastases in patients with breast cancer.
Danazol compared to Tamoxifen used alone Cancer Research
Invasion Metastasis, 2, 177-184, (1982).
Powles TJ, Coombes RC, Gordon C, Smith IE
Administration of prostaglandins A and anti-inflammatory drugs
Vindesine in combination with adriamycin for treatment of
to patients with cancer. IN Advances in Prostaglandin and
metastatic breast cancer. Drugs Exptl Clin Res (5) 57l-575
Coombes RC, Dady P, Parsons C, Ford HT, Gazet J-C, Powles TJ
Coombes RC, Powles TJ, Rees LH, Ratcliffe WA, Nash AG, Henk
Assessment of response of bone metastases to systemic
treatment in patients with breast cancer. Cancer 52: 610-614
Tamoxifen, aminoglutethimide and danazol: Effect of therapy on
hormones in post menopausal patients with breast cancer. Br J
Coombes RC, Perez D, Gazet JC, Ford HT and Powles TJ Danazol
treatment for advanced breast cancer. Cancer Chemother &
Coombes RC, Chilvers Clair, Dowsett M, Gazet J-C, Ford HT,
Bettelheim R, Gordon C, Smith IE, Zava D, Powles TJ
Adjuvant aminoglutethimide therapy for postmenopausal patients
Harris AL, Mitchell M, Smith IE, Powles IE
with primary breast cancer: Progress Report Cancer Research
Suppression of plasma 6-Keto-Prostaglandin F and 13,
14-dihydro-15-keto- prostaglandin F by aminoglutethimide in
advanced breast cancer Br J Cancer (l983) 48, 595-598.
Heckford Susan E, Eccles SA, Powles TJ and Alexander P
Flurbiprofen does not appear to enhance the therapeutic effect of
Muindi J, Coombes RC, Golding S, Powles TJ, Khan O and Husband J
cyclophosphamide. IN Prostaglandins and Cancer: Eds Powles TJ,
The role of computed tomography in the detection of bone
Buckman RS, Honn KV and Ramwell P Pubs Alan R Liss Inc, NY
metastases in breast cancer Br J Radiol 56 233-236 (l983).
Powles TJ, Coombes RC, Harris AL and Smith IE
Aminoglutethimide with hydrocortisone for treatment of
Protection against misonidazole-induced toxicity in vitro
disseminated breast cancer IN Aminoglutethimide Eds RW Elsdon-
by flurbiprofen, a non-steroidal anti-inflammatory agent. IN
Dew, IM Jackson, GFB Birdwood Pubs Roy Soc of Med Academic
Prostaglandins and Cancer: Eds Powles TJ, Bockman RS, Honn KV
Press Inc (London) Limited, Grune & Stratton Inc, NY pp 4l-42
and Ramwell P Pubs Alan R Liss, Inc, NY pp 793-797 (l982).
Coombes RC, Chilvers C, Dowsett M, Bettelheim R, Gordon C,
Present role of hormonal therapy. IN Breast Cancer: Recent
Advances in Diagnosis and Treatment. Ed G Bonadonna, Pubs
Aminoglutethimide as an adjuvant to surgery in poor risk
John Wiley & Sons Ltd pp 229-246 (1982).
postmenopausal patients with breast cancer. IN Aminoglutethimide
Eds. R.W. Elsdon-Dew, I.M. Jackson, G.F.B. Birdwood, Pubs. Roy.
Soc. of Med. Academic Press Inc. (London) Limited, Grune &
Aminoglutethimide in the Treatment of Advanced Postmenopausal
Stratton, Inc., N.Y. pp 37-39 (l983).
Breast Cancer Cancer Research (Suppl) 42 34O5-34O8 (l982).
Harris AL, Powles TJ, Smith IE, Coombes RC, Ford HT, Gazet J-C,
Powles TJ, Coombes RC, Gordon C and Smith IE
Harmer CL, Morgan M, White H, Parsons CA and McKinna JA
A comparison of vindesine vs. vincristine with adriamycin for
Aminoglutethimide for the treatment of advanced postmenopausal
treatment of patients with metastatic or locally recurrent breast
breast cancer. Eur J Cancer Clin Oncol l9(l) pp ll-l7 (l983).
cancer. Eighth Vinca Alkaloid Symposium - Vindesine. ED Marie T
Bakowski. Publishers Ely Lilly pp 65-79 (1982).
Perez DJ, Powles TJ, Milan J, Gazet J-C, Ford HT, McCready VR,
Detection of Breast Carcinoma Metastases in Bone: The Relative
Adjuvant Endocrine Therapy. Reviews on Endocrine - Related
Merits of X rays and Skeletal Scintigraphy. Lancet II 613-616
Coombes RC, Powles TJ, Buckman R, Skilton R, McClelland R,
Breast conservation and its integration with adjuvant
Medical Management of Breast Cancer. IN Symposium on Medical
chemotheray and adjuvant hormone therapy. IN Breast
Management of Malignant Disease Proc. Symposium, Royal
Conservation in the Management of Breast Cancer. Eds Peckham
College of Physicians of Edinburgh, 37-47, (1983).
M and Tobias J Pubs Ed Arnold pp 165-178 (l985).
Perez DJ, Powles TJ, Smith IE, Vincent M, Ashley Susan, Gordon C,
Latissimus dorsi reconstruction of the breast (Letter) BMJ 287,
The Modulating Effects of Flurbiprofen on Adriamycin plus
Vincristine, or Vindesine in the Treatment of Advanced Breast
Cancer. Cancer Chemother & Pharmacol, 15, 278-282, (1985).
Powles TJ The Role of Aromatase Inhibitors in Breast Cancer Seminars in
Gazet J-C, Rainsbury RM, Ford HT, Powles TJ and Coombes RC
Survey of Treatment of Primary Breast Cancer in Great Britain.
British Medical Journal 29O, l793-l795 (l985).
Redding WH, Coombes RC, Monaghan P, Clink HMcD, Imrie SF, Dearnaley DP, Ormerod MG, Sloane JP, Gazet J-C, Powles TJ and
Coombes RC, Powles TJ, Muindi J, Hunt J, Ward M, Perez D and
Detection of micrometastases in patients with primary breast
Trilostane therapy for advanced breast cancer Cancer Treatment
Morris AJR, O’Sullivan JP, Millard FJC, Humberstone AM, Hunt J,
Gazet J-C, Powles TJ, Ford HT and Coombes RC
Vincent MD, Clink H, Coombes RC, Smith IE, Kandler R and
Fibreoptic bronchoscopy as an aid to diagnosis of respiratory
symptoms in breast cancer patients. Br J Cancer 48 731-734
Aminoglutethimide (with hydrocortisone) induced agranulocytosis
in patients with primary breast cancer. British Medical Journal 29l,
Perez DJ, Powles TJ, Gazet J-C, Ford HT and Coombes RC
Mitomycin C, melphalan and methotrexate combination
Powles TJ, Ashley S, Adcock H, Thomas L and Coombes RC
chemotherapy for palliation of disseminated breast cancer.
Therapy of disseminated breast cancer with antioestrogens,
Cancer Chemother and Pharmacol l3 36-38 (l984).
sequentially or in combination with other hormones Excerpta
Clinical trials with Endocrine therapy in Advanced Disease. IN
Waxman JH, Harland SJ, Coombes RC, Wrigley PFM, Malpas JS,
Clinical Trials in Cancer Medicine. Pub. Academic Press. Eds G
Bonnadonna and U Veronesi (1984) 335-342.
The treatment of postmenopausal women with advanced breast
cancer with Buserelin. Cancer Chemotherapy and Pharmacology,
Powles TJ, Ashley S, Ford HT, Gazet J-C, Nash AG, Neville AM and Coombes RC
Treatment of Disseminated Breast Cancer with Tamoxifen,
Aminoglutethimide, Hydrocortisone and Danazol, used in
Criteria for Assessment of Response of Bone Metastases
Combination or Sequentially. Lancet II, 1369-1373 (1984).
to Systemic Therapy. IN Bone Resorption Metastases and
Diphosphonates. Pub. Raven Press, NY Eds. Garrotini, S 93-108
Heusinkveld, R., Valagussa, P., Bonnadonna, G., Powles,T.J. Is T3NoMo Breast Cancer with Pathologically Negative Nodes
Truly Stage III? JCO 242-243 (1984).
Patterns and Mechanisms of bone metastases Proc Roy Soc
Coombes RC, Powles TJ, Easton D, Chilvers CED, Ford HT, Smith IE, McKinnaA, White H, Bradbeer J, Yarnold J, Nash A, Bettleheim
McClelland RA, Berger U, Miller LS, Powles TJ, Jensen EV,
Adjuvant Aminoglutethimide therapy for postmenopausal patients
with primary breast cancer. Breast Cancer: Therapeutic Modalities
Immunocytochemical Assay for Oestrogen Receptor:
Current and Future. Eds Harvey HA, Lipton A, Michaels MA,
Relationship to outcome of therapy in patients with advanced
Pubs MES Medical Education Services (Canada) Toronto, 61-66
breast cancer. Cancer Research (Suppl) 46, 4241-4243 (1986).
Powles TJ, Coombes RC, Smith IE, Chilvers C, Easton D, Thomas L,
Adcock H, Gazet J-C, Nash AG, Bradbeer J, McKinna JA
A Randomised Clinical Trial to compare Tamoxifen with Danazol
A double blind randomised clinical trial of adjuvant amino-
for treatment of benign mammary dysplasia Breast Diseases -
glutethimide versus placebo given to post menopausal patients
with histologically confirmed stage II breast cancer. Breast Cancer
Research and Treatment, 7, 37-40 (1986).
Powles TJ, Ashley S, Forgeson GV, O`Keefe A, Richards L,
Coombes RC, Buckman R, Forrester JA, Shepherd V O`Hare MJ,
Treatment of Advanced Breast Cancer with Mitocycin C,
Mitozantrone and Methotrexate (MMM) compared to vincristine,
In Vitro and in vivo effects of a monoclonal antibody-toxin
anthracycline and cyclophosphamide (VAC). IN Clinical Progress
conjugate for use in autologous bone marrow transplantation for
with Mitozantrone. Eds. G. Bonadonna. Pubs Royal Soc Med
patients with breast cancer. Cancer Research 46, 4217-4220,
Services London, New York. Series No 110, 1-7, (1987).
Goss PE, Ashley S, Powles TJ, Coombes RC
The Detection and Evaluation of Bone Marrow Micrometastases in
High Dose Oral Medroxyprogesterone Acetate in Heavily
Primary Breast Cancer. In Fundamental Problems in Breast Cancer.
Pretreated Patients with Metastatic Breast Cancer. Cancer
Eds. Patterson, AGH Pubs Martinus Nijhoff, 299-301(1987).
Treatment Reports, 70, 777-779 (1986).
Coombes RC, Berger U, Mansi J, Redding H, Powles TJ, Neville AM,
Treatment of Metastatic Breast Cancer as a guide to design
McKinna A, Gazet J-C, Ford HT, Omerod M, McDonnell T
of Adjuvant Therapy Trials. In Fundamental Problems in Breast
Prognostic Significance of Monographs Adjuvant Chemotherapy
Cancer. Eds. Patterson, AGH Pubs Martinus Nijhoff, 369-372
and Endocrine Therapy for Breast Cancer, 1, 51-53, (1986).
Goss PE, Powles TJ, Dowsett M, Hutchison GB, Angela MH,
Endocrine Prevention of Breast Cancer by Tamoxifen IN
Treatment of advanced postmenopausal breast cancer with an
Fundamental Problems in Breast Cancer. Eds Patterson AGH
aromatase inhibitor, 4 - hydroxyandrostenedione - Phase II report.
Pubs Martinus Nijhoff, 139-143, (1987).
Cancer Research 46, 4823-4826 (1986).
Vincent MD, Powles TJ, Skeet R, Ashley S, Coombes RC, Gibb J,
The role of hormonal manipulation in the management of breast
cancer. In Current Management of breast cancer, Toronto: MES
An analysis of possible prognostic features of long term and
Medical Education Services Eds Margolese R Pubs Citation, 8-9
short term survivors of metastatic breast cancer. Eur J Cancer 22,
Powles TJ, Gallagher CJ, Ashley SE, Fenlon D, O`Keeffe AP
Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AMH,
Mitomycin C used in combination with Mitozantrone and
Methotrexate as first line cytotoxic treatment of disseminated
Use of the Aromatase inhibitor, 4 hydroxyandrostenedione in
breast cancer. IN New Trends in Cancer Chemotherapy with
postmenopausal breast cancer: Optimisation of therapeutic dose
Mitomycin C Eds Taguchi T, Andrysek O. Pubs Excerpta Medica,
and route. Cancer Research, 47, 1957-1961 (1987).
Bellamy EA, Nicholas D, Ward M, Coombes RC, Powles TJ,
Prostaglandins and Cancer: Clinical Approaches. IN Prostaglandins
in Cancer Research Eds Garaci E, Paoletti R, Santoro MG, Pubs
Comparison of Computed Tomography and Conventional
Springer-Verlag, Berlin, 184-189 (1987).
Radiology in the assessment of treatment response of lytic bony
metastases in patients with carcinoma of the breast. Clincal
Powles TJ The role of hormonal manipulation in the management of breast
cancer. IN Current Management of Breast Cancer, Toronto: MES
Medical Education Services. Eds. Margolese, R. Pubs. Citation, 8-9,
Tamoxifen and Benign Breast Problems Lancet II, 1070-1072,
Powles TJ, Coombes RC, Berger U, McClelland RA, Trott PA, Wilson
Tests for detecting recurrent disease in the follow up of patients
Prediction of endocrine response in breast cancer by
with breast cancer. Breast Cancer Research and Treatment, 11,
immunocytochemical detection of oestrogen receptor in fine
needle aspirates. Lancet II, 701-703, (1987).
Vincent MD, Powles TJ, Coombes RC, McElwain TJ
Cunningham D, Powles TJ, Dowsett M, Hutchison G, Brodie AMH,
Late intensification with high dose melphalan and autologous
bone marrow support in breast cancer patients responding to
Oral 4-hydroxyandrostenedione, a new endocrine treatment for
conventional chemotherapy. Cancer Chemother and Pharmacol
disseminated breast cancer. Cancer, Chemother and Pharmacol
Gusterson BA, Gullick WJ, Venter DJ, Powles TJ, Elliott C, Ashley SE,
Jones SE, Moon TE, Bonadonna G, Valagussa P, Rivkin S, Buzdar
Immunohistochemical localisation of C-erbB-2 in human breast
Comparison of different trials of adjuvant chemotherapy in stage II
carcinoma. Molecular and Cellular Probes 2, 383-391, (1988).
breast cancer using a natural history data base (NHDB). Am J Clin
Gusterson BA, Machin LG, Gullick WJ, Gibbs NM, Powles TJ, Price
McClelland RA, Berger U, Wilson P, Powles TJ, Trott PA, Easton D,
Immunohistochemical distribution of C-erbB-2 in infiltrating and in
situ breast cancer. Int J Cancer 42, 842-845 (1988).
Presurgical determination of estrogen receptor status using
immunocytochemically stained fine needle aspirate smears in
Travers MT, Barrett-Lee PJ, Berger U, Luqmani YA, Gazet J-C,
patients with breast cancer. Cancer Research, 47, 6118-6122,
Growth factor expression in normal, benign and malignant breast
tissue. British Medical Journal 296, 1621-1624, (1988).
Coombes RC, Powles TJ, Easton D, Chilvers C, Ford HT, Smith IE,
McKinna A, White H, Bradbeer J, Yarnold J, Nash AG, Bettelheim R,
Gusterson BA, Machin LG, Gullick WJ, Gibbs NM, Powles TJ, Elliott
Dowsett M, Gazet J-C and Investigators of the Collaborative Breast
c-erbB-2 expression in benign and malignant breast disease. Br J
Adjuvant aminoglutethimide therapy for post-menopausal patients
with primary breast cancer Cancer Research, 47, 2496-2499, (1987).
Hardy JR, Powles TJ, Coombes RC, Ashley S
Epirubicin compared with doxorubicin with vincristine and
Vincent MD, Powles TJ, Ford HT, Gazet JC
cyclophosphamide in advanced breast cancer. Proceedings of the
Excision of solitary lung metastases from two patients with breast
Pharmorubicin Update 1988 Symposium. Pubs Medicom (UK)
Myelosuppression after methotrexate, mitozantrone and mitomycin
Treatment of menopausal symptoms in breast cancer patients.
C for the treatment of advanced breast cancer. (Letter) Lancet ii
Mansi JL, Berger V, Easton D, McDonnell T, Redding WH, Gazet
A Feasibility trial of tamoxifen chemoprevention of breast cancer
in Great Britain. Cancer Investigation 6(5) 621-624 (1988).
Bone marrow micrometastases in patients with primary breast cancer: An early predictor of bone metastases. British Medical
Nash AG, Powles TJ Review of a hospital experience of breast abscesses Br J Surgery
Powles TJ Advanced breast cancer - New approaches to treatment. Eur J Clinical Clin Oncol, 24, 95-98, (1988).
Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey
Svensson WE, Al-Murrani B, Blaszcyzk M, Cosgrove DO, Hounsom
JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD, Tillyer CR,
A, Jones A, Powles TJ, Sinnett HD, Tohno E, Vagios E
Confusing appearances on breast ultrasound caused by fine
A pilot trial to evaluate the acute toxicity and feasibility of
needle aspirtion Br J Radiol 63, 400 (1990).
tamoxifen for prevention of breast cancer Br J Cancer 60
Hardy JR, Powles TJ, Judson IR, Sinnett D, Ashley SE, Coombes RC,
Olliff JFC, Hardy JR, Williams MP, Powles TJ
Combination hormone treatment with tamoxifen,
Case Report: Magnetic resonance imaging of spinal amyloid.
aminoglutethimide, danazol and medroxyprogesterone acetate in
Clinical Radiology (1989) 40, 632-633.
advanced breast cancer Eur J Cancer Vol 26, 7, 824-827 1990.
Treatment of breast cancer with aromatase inhibitors - current
Tamoxifen and oestrogen replacement (Letter) Lancet ii (1990)
status and future prospects Br J Cancer 60, 5-8 (1989).
Hardy JR, Powles TJ, Judson I, Heron C, Williams M, Cherryman G,
Oral contraceptives and breast cancer Lancet ii 97 (1989) Letter.
Husband J, Cosgrove D, Blaszcyzzyk M, Sinnett HD, Ashley SE,
How many tests are required in the diagnosis of palpable breast
Powles TJ, Hardy JR, Ashley SE, Cosgrove D, Davey JB, Dowsett M,
abnormalities? Clinical Oncology 2, 148-152 (1990).
McKinna JA, Nash AG, Rundle SK, Sinnett HD, Tillyer CR, Treleaven JG
Chemoprevention of breast cancer Breast Cancer Res Treatment
Metastatic breast cancer Oncology Commentary 3: 1-2 (1990).
Powles TJ, Tillyer CR, Jones AL, Ashley SE, Treleaven J, Davey JB,
A Chemoprevention of breast cancer Acta Oncologica 28 865-
Prevention of breast cancer with tamoxifen - an update on the
Royal Marsden Hospital pilot programme Eur J Cancer 26,
Powles TJ, Jones AL, Ashley SE, Tidy A Menstrual effect on surgical cure of breast cancer - Letter Lancet ii
Brada M, Rowley M, Grant DJ, Ashley S, Powles TJ
Hypercalcaemia in patients with disseminated breast cancer Acta
Lonning PE, Dowsett M, Jacobs S, Schem B, Hardy J, Powles TJ Lack of diurnal variation in plasma levels of androstenedione,
testosterone, estrone and estradiol in postmenopausal women
J Steroid Biochem 34, 551-553 (1989).
Ranitidine induced thrombocytopenia and pancytopenia in
patients on prophylactic ranitidine Eur J Int Med 2: 183-185
Lonning PE, Dowsett M, Powles TJ Postmenopausal estrogen synthesis and metabolism: alterations
caused by aromatase inhibitors used for treatment of breast
Powles TJ, Trott PA, S, Cherryman G, Clarke S, Ashley S, Coombes
cancer. Steroid Biochemistry 35, 355-366 (1990).
Fine needle aspiration cytodiagnosis as a pre requisite for primary
medical treatment of breast cancer Cytopathology 2, 7-12 (1991).
Jones AL, Williams MP, Powles RJ, Oliff JFC, Hardy JR, Cherryman G, Husband J
Magentic resonance imaging in the detection of skeletal
Jones AL, Forgeson GV, Powles TJ, Coombes RC
metastases in patients with breast cancer Br J Cancer 62,
A clinical study of nafazatrom in advanced human breast cancer
Cancer Chemother Pharmacol (1991) 27(4): 326-8.
Powles TJ, Jones AL, Judson IR, Hardy JR, Ashley SE
Tamoxifen breast cancer remission: estrogenic or antiestrogenic?
A randomised trial comparing combination chemotherapy
using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer Br J Cancer, 64; 406-410, (1991).
Haynes BP, Jarman M, Dowsett M, Mehta A, Lonning PE, Griggs
Glaholm J, Collins D, Mansi J, Sharp JC, Leach MO, McCready VR,
Pharmacokinetics and pharmacodynamics of the aromatase
The importance of signal localisation and measurement of
inhibitor 3-ethyl-3-(4- pyridyl)piperidine-2,6-dione in
absolute metabolite changes when monitoring the treatment
postmenopausal breast cancer patients Cancer Chemother
response of human breast carcinoma with in-vivo 31P NMR
spectroscopy. In Radioaktive Isotope in Klinik und Forschung. Eds
R Höfer, H Bergmann and H Sinzinger. Schuattauer Stuttgart New
Jones AL, Dowsett MJ, Powles TJ, Gallagher CJ, Coombes RC Treatment of advanced breast cancer with miconazole: a potential
inhibitor of peripheral oestrogen synthesis Eur J Cancer 27(3)
Powles TJ, Gazet JC, Ford HT, Ashley SE, Nash AG, Tidy VA
Timing of Surgery for premenopausal breast cancer in relation
to the last menstrual period (Letter) Lancet, 337: 1603-1604
Jones AL, Powles TJ The use of tamoxifen in malignant breast disease Maternal & Child
Chemoprevention of Breast Cancer with Tamoxifen
Chemoimmunoprevention of Cancer. Eds: Pastorio U & Hong WK.
Thieme Medical Publishers, Inc., New York 225-229, (1991).
Antiosteolytic treatments for skeletal metastases: General principles and clinical relsults In Tumour induced hypercalcaemia
and its management Eds Russell RGG, Kanis JA Royal Society of
Paterson AHG, Ernst DS, Powles TJ, Ashley S, McCloskey EV, Kanis JA
Medicine Services Ltd, London, New York 71-92 (1991).
Treatment of skeletal disease in breast cancer with clodronate
Bone, 12 (suppl. 1), S25-S30, (1991).
Lonning PE, Jacobs S, Jones A, Haynes B, Powles T, Dowsett M
The influence of CGS16949A on peripheral aromatisation in
Dowsett M, Mehta A, King N, Smith IE, Powles TJ, Stein RC,
breast cancer patients Br J Cancer 63: 789-93 (1991).
An endocrine and pharmacokinetic study of 4 oral doses of
4-hydroxyandrostenedione in postmenopausal breast cancer
patients Eur J Cancer, 28, 415-420, 1992.
Chemoprevention of breast cancer with tamoxifen IN Medical Management of Breast Cancer. Eds Powles TJ and Smith IE
Publisher Martin Dunitz 1991. pp 161-166.
Jones AL, MacNeill F, Jacobs S, Lonning PE, Dowsett M, Powles TJ
The influence for intramuscular 4 hydroxyandrostenedione on
peripheral aromatisation in breast cancer patients Eur J Cancer,
Paterson AHG, Ernst DS, Powles TJ, Ashley S, Kanis JA, McCloskey EV
The use of clodronate in patients with breast cancer Eur J Cancer (Suppl) - In press 1991.
Powles TJ, Smith IE (Letter on overview).
Adjuvant treatment in breast cancer Lancet, 339, 423, (1992)
Dowsett M, MacNeill F, Mehta A, Newton C, Haynes B, Jones A, Jarman M, Lonning PE, Powles TJ, Coombes RC
Endocrine, pharmacokinetic and clinical studies of the
Bliss JM, Selby PJ, Robertson B, Powles TJ
aromatase inhibitor 3-thyl-3-(4- pyridyl)piperidine-2,6-dione
A method for assessing the quality of life of cancer patients:
(“pyridoglutethimide”) in postmenopausal breast cancer patients
replication of the factor structure Brit J Cancer, 65: 961-966
British Journal of Cancer (1991) 64: 887-894.
Talbot DC, Smith IE, Nicolson M, Powles TJ, Button D, Walling J
Talking point - On trial: Drugs that may prevent disease New
A phase II trial of the novel sulphonylurea sulofenur (LY186641)
in advanced breast cancer Cancer Chemotherapy & Pharmacology,
Clodronate: the potential for the future Bone, 12, (Suppl. 1)
Jones AL, Powles TJ, Treleavan J, Burman JF, Nicolson MC, Chung
H-I, Ashley SE Haemostatic changes and thromboembolic risk
during tamoxifen therapy in normal women Brit J Cancer, 66; 744-
Powles TJ Prevention of breast cancer Current Opinion in Oncology (1991) 3: 1024-1028.
Jones AL, Powles TJ, Law M, Tidy A, Easton D, Coombes RC, Smith
Montes A, Powles TJ, O’Brien MER, Ashley SE, Luckitt J, Treleavan J
IE, McKinna JA, Nash A, Ford HT, Gazet JC
A toxic interaction between mitomycin C and tamoxifen causing
Adjuvant Aminoglutethimide for post-menopausal patients with
the haemolytic uraemic syndrome Eur J Cancer 29A(13): 1854-
primary breast cancer: analysis at eight years J Clin Oncol, 10:
Lønning PE, Dowsett M, Jones A, Ekse D, Jacobs S, MacNeill F,
Current Practice in Surgery 1993; 5: 162-165.
Influence of aminoglutethimide on plasma oestrogen levels in
breast cancer patients on 4-Hydroxyandrostenedione treatment
Breast Cancer Research & Treatment, 23: 57-62, 1992.
Prevention of metastases with bisphosphonates Canadian Journal
of Diagnosis 1993; (supplement) 37-40.
Tamoxifen in the endocrine prevention of breast cancer Endocrine
Powles TJ, Hickish T, Casey S, O’Brien M
Aspects of Breast Cancer, 37-39, (1992).
Hormone replacement therapy after breast cancer - Letter Lancet
The development of cancer chemoprevention trials In: Introducing
New Treatments for Cancer: Practical, Ethical and Legal Problems.
Tamoxifen in the prevention of breast cancer: Are the Risks likely
Ed: Williams CJ, John Wiley & Sons, England (1992).
to outweigh the benefits? Drug Saf (1993) 10: 1-4.
MacNeill FA, Jones AL, Jacobs S, Lønning PE, Powles TJ, Dowsett M
The influence of Aminoglutethimide and its analogue Rogletimide
Screening of inherited breast cancer with DNA markers (Letter)
on peripheral aromatisation in breast cancer Brit J Cancer,
Jones AL, Powles TJ Chemoprevention of breast cancer
Review on Endocrine-Related Cancer 43: 33-42 (1993).
The case for clinical trials of tamoxifen for prevention of breast cancer - A Personal View Lancet, 340: 1145-47, 1992.
Kanis J, McCloskey E, O’Rourke N, Khan S, Fern D, Eyres K, Sirtori
Ricketts D, Hadcocks L, Fitzek M, Rawson NSB, Colston K, Powles
A Clodronate in hypercalcaemia and osteolytic bone disease due
to breast cancer. Saudi Medical Journal 14(2):93-97 (1993).
Serum markers for primary and recurrent breast cancer; BCM-EIA, CAM 26 and CAM 29 Tumour Biology (1992) 13: 207-216.
Clodronate decreases skeletal morbidity in p;atients with bone
metastases from breast cancer: A double blind randomised
Current Controversies in the Endocrine Therapy of Advanced
controlled trial. In: Metastatic Bone Disease. Eds Diel, Kaufmann,
Breast Cancer Oncology 1992; 49: 18-21.
Bastert Publisher Springer-Verlag, Heidelberg. 1993, p 177-179
Treatment of metastatic bone disease with clodronate Therapy
MMM (Mitozantrone, Methotrexate and Mitomycin C):
An effective new regimen in the treatment of metastatic breast
cancer. Oncology 50 (Suppl 1) 9-15 (1993).
Jacobs S, MacNeill F, Lonning P, Dowsett M, Jones A, Powles TJ
Aromatase activity, serum oestradiol and their correlation with
Murray PA, Gomm J, Ricketts D, Powles TJ, Coombes RC
demographic indices J Steroid Biochem Mol Biol 41 769-771
The effect of endocrine therapy on the levels of oestrogen and
progesterone receptor and transforming growth factor beta-1 in
metastatic human breast cancer: an immunocytochemical study
Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J,
Eur J Cancer 30(A) No 9: 1218-1222 (1994).
Ashley SE Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer J Clin Oncol 11(1): 59-65 (1993).
Powles TJ, Jones AL, Ashley SE, O’Brien MER, Tidy VA, Treleavan J,
Powles TJ, Hickish TF, Makris A, Ashley SE, O’Brien M. Tidy V,
Cosgrove D, Nash AG, Sacks N, Baum M, McKinna JA, Davey JB
Casey S, Nash AG, Sacks N, Cosgrove D, MacVicar D, Fernando I,
The Royal Marsden Hospital pilot tamoxifen chemoprevention trial
Breast Cancer Research and Treatment 31: 73-82 (1994).
A randomised trial of chemo-endocrine therapy started before
(neoadjuvant) or after (adjuvant) surgery for treatment of primary
breast cancer Journal of Clinical Oncology, 13: 547-552, 1995.
Dowsett M, Smithers D, Moore JW, Trunet P, Coombes RC, Powles TJ, Rubens RD, Smith IE
Endocrine changes with aromatase inhibitor fadrozole
Martin EA, Rich KJ, White INH, Woods KL, Powles TJ, Smith LL
hydrochloride in breast cancer Eur J Cancer 30A(10): 1453-58
32P-postlabelled DNA adducts in liver obtained from women
treated with tamoxifen Carcinogenesis 16(7): 1651-54 (1995).
Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove
Makris A, Powles TJ, Dowsett M, Allred C.
p53 protein overexpression and chemosensitivity in breast cancer
Effects of tamoxifen on the uterus and ovaries of women involved
in a randomised breast cancer prevention trial. Lancet 343: 1318-
Breast cancer response to hormone replacement therapy
MacNeill FA, Jacobs S, Lonning PE, Powles TJ, Dowsett M.
withdrawal (letter). Lancet 1995: 345: 1442.
Combined treatment with 4-Hydroxyandrostenedione and
aminoglutethimide: effects on aromatase inhibition and oestrogen
Fernando IN, Powles TJ, Dowsett M, Ashley S, McRobert L, Titley J,
suppression. Br J Cancer 69; 1171-1175 (1994).
Ormerod MG, Sacks N, Nicolson MC, Nash A, Ford HT, Allan SM,
Powles TJ, Montes A, O’Brien M. Ashley SE, Nash AG, Sacks
Determining factors which predict response to primary medical
N, Ford HT, Fernando I, Cosgrove D. Mitoxantrone combination
therapy in breast cancer using a single fine needle aspirate with
chemotherapy used with tamoxifen in the neoadjuvant therapy of
immunocytochemical staining and flow cytometry. Virchows Archiv
breast cancer. In: Pharmanual: Mitoxantrone in the treatment of
early breast cancer. Ed G Bonadonna. PharmaLibri, Chicago 41-49
Tamoxifen therapy and carcinogenic risk (Editorial). Journal of the
O’Brien MER, Casey S, Treleaven J, Powles TJ.
National Cancer Institute, 1995; 87: 1343-45.
Use of Erythropoietin in the management of the haemolytic
uraemic syndrome induced by Mitomycin C/tamoxifen European
Paterson AHG, Kanis JA, Powles TJ, McCloskey E, Hanson J, Ashley
Journal of Cancer 30A (6): 894-895 (1994) (Letter).
S. Role of bisphosphonates in prevention and treatment of bone
metastases from breast cancer. Canadian Journal of Oncology
O’Brien MER, Nicolson M, Montes A, Tidy A, Ashley S, Powles TJ
Phase 1 study of mitozantrone, methotrexate and mitomycin with
granulocyte colony- stimulating factor (filgrastim) in patients with
advanced breast cancer British Journal of Cancer, 70: 980-983
Hormone replacement therapy as treatment of breast cancer - a
phase II study of Org OD 14 (Tibolone) British Journal of Cancer
Endometrial cancer during tamoxifen treatment. Lancet 343:
The management of women with a high risk of breast cancer:
The role of prophylactic tamoxifen. In: Genetic Predisposition to
Fernando I, Titley JC, Powles TJ, Dowsett M, Trott PA, Ashley SE,
Cancer. Eds: Eeles, Ponder, Easton, Horwich. Chapman and Hall,
Measurement of S-phase fraction and ploidy in sequential fine-
needle aspirates from primary human breast tumours treated with
Powles TJ, Hickish T, Kanis JA, Tidy VA, Ashley S.
tamoxifen British Journal of Cancer 1994; 70: 1211-16.
The effect of tamoxifen on bone mineral density measured by dual energy xray absorptiometry in healthy pre and postmenopausal women. J Clin Oncol 1996: 14(1): 78-84.
Bonnefoi HR, Smith IE, Dowsett M, Trunet PF, Huston SJ, da Luz
Fernando IN, Powles TJ, Ashley S, Grafton D, Harmer CL, Ford HT.
An acute toxicity study on the effects of synchronous
Therapeutic effects of the aromatase inhibitor fadrozole
chemotherapy and radiotherapy in early stage breast cancer after
hydrochloride in advanced breast cancer. British Journal of Cancer
conservative surgery. Clinical Oncology 1996; 8: 234-238.
Kanis JA, Powles TJ, Paterson AHG, McCloskey EV, Ashley S.
Efficacy of tamoxifen as treatment of breast cancer. Seminars in
Clodronate decreases the frequency of skeletal metastases in
Oncology 1997; 24(1) Suppl 1: 48-54.
women with breast cancer. Bone 1996; 19: 663-667.
Bonnefoi H, Smith IE, O’Brien MER, Seymour MT, Powles TJ, Allum
Chemotherapy and Endocrine Manipulation. In: Clinical Endocrine
Oncology. Eds: Sheaves R, Jenkins P, Wass J. Blackwell Science,
Phase II study of continuous infusional 5-fluorouracil with
epirubicin and carboplatin (instead of cisplatin) in patients with
metastatic/locally advanced breast cancer (infusional E-carbo-F): a
very active and well tolerated outpatient regimen. British Journal of
Chemoprevention of breast cancer: why is tamoxifen not the
answer? Endocrine-Related Cancer 1997; 4: 135-139.
Chang J, Powles TJ, Ashley SE, Gregory RK, Tidy VA, Singh R.
The effect of tamoxifen and hormone replacement therapy on
Breast Cancer Chemoprevention. In: Bonadonna G, Hortobagyi
serum cholesterol, bone mineral density and coagulation factors in
GN, Gianni AM (eds). Textbook of Breast Cancer - A Clinical Guide
healthy women participating in a randomised, controlled tamoxifen
to Therapy. Martin Dunitz Ltd, London. 1997 pp 335-340.
prevention study. Annals of Oncology1996; 7: 671-675.
Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando
Vinnicombe SJ, MacVicar AD, Guy RL, Sloane JP, Powles TJ, Knee
IN, Ashley S, Ormerod MG, Titley JC, Gregory RK and Allred DC.
Prediction of response to neoadjuvant chemoendocrine therapy
Primary breast cancer: Mammographic changes after neoadjuvant
in primary breast carcinomas. Clinical Cancer Research 1997; 3:
chemotherapy, with pathologic correlation. Radiology 1996; 198:
Makris A, Allred DC, Powles TJ, Dowsett M, Fernando IN, Trott PA,
Gregory RK, Chang J, Singh R, Powles TJ.
Ashley SE, Ormerod MG, Titley JC, Osborne CK.
Clubbing, Arthralgia and Haemoptysis in a patient with metastatic
Cytological evaluation of biological prognostic markers from
carcinoma of the breast.Annals of Oncology 1996; 7: 756-757.
primary breast carcinomas. Breast Cancer Research and Treatment
Dowsett M, Makris, Ellis P, Johnston SRD, Salter J, Detre S,
Humphries S, Saccani- Jotti G, Powles TJ, Smith IE.
Oncogene products and other diagnostic markers in human breast
Chemoprevention of breast cancer using tamoxifen. Endocrine-
cancer patients, in Castagnetta L, Nenci I, Bradlow HL (eds). Basis
Related Cancer: Special Beatson Centenary Issue 1997; 4(3):
for cancer management. Annals of the New York Academy of
Sciences, vol 784. New York Academiy of Sciences (New York) 1996, pp 403-411.
Gregory RK, Chang J, Powles TJ, Treleavan J. Leukaemic infiltration
or primary carcinoma of the breast in a patient with acute myeloid
Thirlaway K, Fallowfield L, Nunnerley H, Powles T.
leukaemia? The Breast 1997; 6: 303-305.
Anxiety in women ‘at risk’ of developing breast cancer. (Short communication). British Journal of Cancer (1996) 73: 1422-24.
Adjuvant therapy for early breast cancer: a time to refine
Fernando IN, Ford HT, Powles TJ, Ashley S, Glees JP, Torr M,
(Editorial). JNCI 1997; 89 (22): 1652-54.
Grafton D, Harmer CL. Factors affecting acute skin toxicity in patients having breast
irradiation after conservative surgery: a prospective study of
treatment practice at the Royal Marsden Hospital. Clinical
Evolving clinical strategies: innovative approaches to the use of
mitoxantrone. European Journal of Cancer Care 1997; 6, Suppl 1: 1-3.
Gregory RK, Powles TJ, Chang JC, Ashley S.
Makris A, Powles TJ, Ashley SE, Chang J, Hickish T, Tidy VA,
A randomised trial of six versus twelve courses of chemotherapy
in metastatic carcinoma of the breast. European Journal of Cancer
Ford HT. A reduction in the requirements for mastectomy in a
randomized trial of neoadjuvant chemoendocrine therapy in
primary breast cancer. Annals of Oncology 1998; 9: 1179-1184.
J Chang, TJ Powles, SE Ashley, T Iveson, RK Gregory, M Dowsett.
Variation in endometrial thickening in women with amenorrhea
Makris A, Powles TJ, Allred DC, Ashley SE, Trott PA, Ormerod MG,
on tamoxifen. Breast Cancer Research and Treatment 1998; 48:
Quantitative changes in cytological molecular markers during
primary medical treatment of breast cancer: A pilot study. Breast
Makris A, Powles TJ, Allred DC, Ashley S, Ormerod MG, Titley JC,
Cancer Research and Treatment 1999; 53: 51-59.
Changes in hormone receptors and proliferation markers in
tamoxifen treated breast cancer patients and the relationship with
A review of results from the NSABP and Royal Marsden
response. Breast Cancer Research and Treatment 1998; 48:
chemoprevention trials. Primary Care and Cancer 1999, 19 (3):
M Dowsett, C Archer, L Assersohn, RK Gregory, P Ellis, J Salter,
Hormone status of in situ cancer in BRCA1/BRCA2 mutation
J Chang, P Mainwaring, I Boedinghaus, S Johnston, TJ Powles, IE
carriers (Letter). Lancet 1998; 351: 1487.
Clinical studies of apoptosis and proliferation in breast cancer.
TJ Powles, E McCloskey, AHG Paterson, S Ashley, VA Tidy,
Endocrine-Related Cancer 1999; 6: 25-28.
Oral clodronate and reduction in loss of bone mineral density in
women with operable primary breast cancer. J Nat Cancer Inst
Tamoxifen for prevention of breast cancer: Report of the National
Surgical Adjuvant Breast and Bowel Project P-1 Study (Letter).
Prognostic impact of amenorrhoea after adjuvant chemotherapy
in premenopausal breast cancer patients with axillary node
Breast cancer chemoprevention trials using tamoxifen. Oncology in
involvement - Editorial Eur J Cancer 1998; 34(5): 603-605.
Powles TJ, Bourne T, Athanasiou S, Chang J, Grübock K, Ashley S,
Leach MO, Verrill M, Glaholm J, Smith TA, Collins DJ, Payne
Oakes L, Tidy A, Davey J, Viggers J, Humphries S, Collins W.
GS, Sharp JC, Ronen SM, McCready VR, Powles TJ, Smith IE.
The effects of norethisterone on endometrial abnormalities
Measurements of human breast cancer using magnetic resonance
identified by transvaginal ultrasound screening of healthy
spectroscopy: a review of clinical measurements and a report
postmenopausal women on tamoxifen or placebo. British Journal
of localized 31P measurements of response to treatment. NMR
Powles TJ, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy
Breast cancer prevention using tamoxifen. In: Breast cancer:
Interim analysis of the incidence of breast cancer in the Royal
Sharing the decision. A Maslin & TJ Powles (Eds) Oxford
Marsden Hospital tamoxifen randomised chemoprevention trial.
University Press, England, 1999; pp 165-177.
Cummings SR, Eckert S, Krueger K, Grady D, Powles TJ, Cauley,
JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME,
Status of anti-oestrogen breast cancer prevention trials.
Black D, Glusman JE, Costa A, Jordan VC.
The effect of raloxifene on risk of breast cancer in postmenopausal
women. Results from the MORE randomized trial. JAMA 1999; 281:
Tamoxifen’s oestrogen-like effects in a breast cancer chemoprevention trial. Eur J Cancer 1998 34: S17-S18.
Makris A, Powles TJ, Kakolyris S, Dowsett M, Ashley SE, Harris
K Gregory, TJ Powles, J Salter, JC Change, S Ashley, M Dowsett.
AL. Reduction in angiogenesis after neoadjuvant chemoendocrine
Prognostic relevance of cerbB2 expression following neoadjuvant
therapy in operable breast cancer. Cancer 1999; 85: 1996-2000.
chemotherapy in patients in a randomised trial of neoadjuvant
versus adjuvant chemoendocrine therapy. Breast Cancer
Research and Treatment 2000; 59(2): 171-175.
TJ Powles. Breast cancer prevention. Update 1999; 59(4): 252.
Chemoprevention options for BRCA1 and BRCA2 mutation
J Chang, TJ Powles, DC Allred, SE Ashley, GM Clark, A Makris, L
carriers. J Clin Oncol 2000; 18(21 suppl): 93S-99S.
Assersohn, RK Gregory, CK Osborne, M Dowsett. Biologic markers as predictors of clinical outcome from systemic
therapy for primary operable breast cancer. J Clin Oncol 1999;
Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M.
Apoptosis and proliferation as predictors of chemotherapy
response in patients with breast carcinoma. Cancer 2000;
L Assersohn & T J Powles. Primary medical treatment - the results of the NSABP-B18 trial
and the Royal Marsden Hospital trial. In: Primary medical therapy
Cauley JA, Norton L, Lippman ME, Eckeert S, Krueger KA, Purdie
for breast cancer: Clinical and Biological aspects. European School
DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles
of Oncology Scientific Update, volume 4. Eds: M Dowsett, A
TJ, Morrow M. Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore
Howell. Pubs: Elsevier Science. 1999; pp 3-11.
Continued breast cancer risk reduction in postmenopausal women
treated with raloxifene: 4 year results from the MORE trial. Multiple
outcomes of raloxifene evaluation. Breast Cancer Research and
Breast cancer prevention – Commentary. Breast Cancer Research
LJ Fallowfield, A Fleissig, R Edwards, A West, TJ Powles, A Howell,
L Assersohn, TJ Powles, AG Nash, AJ Neal, N Sacks, J Chang,
Tamoxifen for the prevention of breast cancer: Psychosocial
Local relapse in primary breast cancer patients with unexcised
impact on women participating in randomised controlled trials.
positive surgical margins after lumpectomy, radiotherapy and
chemoendocrine therapy. Annals of Oncology 1999; 10: 1451-1455.
Results and implications of the Royal Marsden and other
J Chang, TJ Powles, DC Allred, SE Ashley, A Makris, RK Gregory, CK
tamoxifen chemoprevention trials. Clinical Breast Cancer 2001;
Prediction of clinical outcome from primary tamoxifen of biologic markers in breast cancer patients. Clinical Cancer Research 2000;
The Royal Marsden Hospital (RMH) Trial – key points and
remaining questions. Ann N Y Acad Sci. 2001 Dec;949:109-12.
TJ Powles Current controversies in cancer: Tamoxifen for breast cancer
prevention Eur J Cancer 2000; 36: 142-150.
Breast Cancer Prevention. The Oncologist 2002; 7(1): 60-64.
R Saso, S Kulkarni, P Mitchell, J Treleaven, G Swansbury, J Mehta,
Secondary myelodysplastic syndrome/acute myeloid leukaemia
Use of selective anti-oestrogens for the chemoprevention of
following mitoxantrone-based therapy for breast carcinoma. British
breast cancer. In: Miller/Ingle (Eds). Endocrine therapy of breast
Journal of Cancer, 2000; 83(1): 91-94.
cancer. Marcel Dekker Inc. New York. 2002 pp 303-308.
Gene expression profiles derived from fine needle aspiration
Combined treatment with buserelin and tamoxifen in
correlate with response to systemic chemotherapy in breast
premenopausal 3 (0 metastatic breast cancer: a randomized
cancer Christos Sotiriou, Trevor J Powles, Mitch Dowsett, Amir
study. (Letter). JNCI 2000; 92: 2040.
A Jazaeri, Andrew L Feldman, Laura Assersohn, Chandramouli Gadisetti, Steven K Libutti, Edison T Liu Breast Cancer Res 2002, 4: R3.
L Assersohn, L Gangi, Y Zhao, M Dowsett, R Simon, TJ Powles,
Sari Atula, Trevor Powles, Alexander Paterson Eugene McCloskey,
The feasibility of using fine needle aspiration from primary breast
Extended Safety Profile of Oral Clodronate After Long-Term Use
cancers for cDNA microarray analyses. Clinical Cancer Research
in Primary Breast Cancer Patients. Drug Safety 2003; 26 (9):
Neoadjuvant chemotherapy for operable breast cancer – review
Isoflavones commentary. Breast Cancer Research 2004 6(3)
TJ Powles, S Paterson, JA Kanis, E McCloskey, S Ashley, A Tidy,
S Martino, J A Cauley, E Barrett-Connor, T J Powles, J Mershon, D
K Rosenqvist, I Smith L Ottestad, S Legault, M Pajunen, A
Nevantaus, E Männistö, A Suovuori, S Atula, J Nevalainen, L
Continuing Outcomes Relevant to Evista: Breast Cancer Incidence
in Postmenopausal Osteoporotic Women in a Randomized Trial of
A randomised placebo controlled trial of clodronate in patients
Raloxifene. JNCI 2004; 96(23) 1751-1961.
with primary operable breast cancer. JCO 2002; 20: 3219-3224.
Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle J, Edge S,
Endocrine Prevention of Breast Cancer. Euro J Cancer Supplement
Mamounas EP, Gralow J, Goldstein LJ, Pritchard K, Brawn S, Cobleigh
MA, Langer AM, Perotti J, Powles TJ, Whelan TJ, Browman GP.
American Society of Clinical Oncology Technology Assessment on
Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN,
the use of aromatase inhibitors as adjuvant therapy for women
Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard
with hormone receptor-positive breast cancer: Status report
KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan
American Society of Clinical Oncology assessment on the use
IBIS Working Party & Principal Investigators. First results from
of aromatase inhibitors as adjuvant therapy for postmenopausal
the International Breast Cancer Intervention Trial (IBIS-1): a
women with hormone receptor-positive breast cancer: Status
randomised prevention trial. Lancet 2002; 360:817 - 824.
report 2004. J Clin Oncol 2005 23(3): 619-629.
R Erkkola, L Mattila, T Powles, J Heikkinen, B Toivola, P Korhonen,
Endocrine therapy of breast cancer. In: Wass/Shalet (Eds). Oxford
Textbook of Endocrinology and Diabetes. Pubs: Oxford University
Bone mineral density and lipid changes during 5 years of follow
up in a study of prevention of breast cancer with toremifene
in healthy, high-risk pre- and postmenopausal women. Breast
Cancer Research and Development 2005 – In Press.
Powles TJ. Anti-oestrogenic prevention of breast cancer – the make or break
point. Nature Reviews Cancer 2002; 2: 787-794.
Practical considerations in bone metastases in breast cancer.
Business Briefing – Longterm Healthcare 2005, pp 14-18.
Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P.
Overview of the main outcomes in the breast cancer prevention
Trevor Powles, Alexander Paterson, Eugene McCloskey, Phil
Schein, Bobbi Scheffler, Alwynne Tidy, Sue Ashley, Ian Smith,
Reduction in Bone Relapse and Improved Survival with Oral
Clodronate for Adjuvant Treatment of Operable Breast Cancer.
Anti-oestrogenic chemoprevention of breast cancer – the need to
Breast Cancer Research 2006, 8: R13.
progress. Euro J Cancer 2003; 39: 572-579.
R Padhani, C Hayes, L Assersohn, T J Powles, A Makris, J Suckling,
Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle
JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ,
Prediction of clinico-pathological response of breast cancer to
Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ,
primary chemotherapy at contrast-enhanced MRI imaging: initial
clinical results. Radiology 2006, 239(2): 361-74.
American Society of Clinical Oncology Technology Assessment Working Group Update: Use of aromatase inhibitors in the adjuvant setting. J Clin Oncology 2003; 21:
M Lopez, C J Lelliott, S Tovar, W Kimber, R Gallego, S Virtue, M
Blount, M Vazquez, N Finer, TJ Powles, S O’Rahilly, AK Saha, C
Review: Improvements in tumor targeting, survivorship and
Tamoxifen-induced anorexia is associated with fatty acid synthase
chemoprevention pioneered by tamoxifen (V C Jordan).
inhibition in the ventromedial nucleus of the hypothalamus and
accumulation of malonyl-CoA. Diabetes 2006; 55: 1327-1336.
Z Kote-Jarai, TJ Powles, G Mitchell, A Tidy, S Ashley, D Easton, L
Oral clodronate (Bonefos®) in women with primary breast
Assersohn, N Sodha, J Salter, B Gusterson, M Dowsett, R Eeles.
cancer: Effects on bone turnover and skeletal metastases. Poster
BRCA1/BRCA2 mutation status and analysis of cancer family
presented at the 5th European Breast Cancer Conference, March
history in participants of the Royal Marsden Hospital tamoxifen
chemoprevention trial. Cancer Letters 2007; 247(2): 259-65.
Trevor J. Powles; Sue Ashley; Ian E. Smith; Mitch Dowsett
Prevention of Breast Cancer using Selective Oestrogen Receptor
Response: Re: Treatment of human epidermal growth factor
Modulators (SERMs). Breast Cancer Research 2006 8: 111.
receptor 2-overexpressing breast cancer xenografts with
multiagent human epidermal growth factor receptor-targeted
A Lipton, J Berenson, J-J Body, B Boyce, O Bruland, M Carducci,
therapy. JNCI 2007;99 (21): 1644-46.
C Cleeland, D Clohisy, R Coleman, R Cook, T Guise, R Pearse, T
Powles, M Rogers, G Roodman, M Smith, L Suva, R Vessella, K
T J Powles, A Howell, D Gareth Evans, E V McCloskey, S Ashley, R
Advances in treatment metastatic bone cancer: Summary
Red clover isoflavones are safe and well-tolerated in women with
Statement for the First Cambridge Conference. Clinical Cancer
a family history of breast cancer. Menopause International 2008;
Research, 2006; 12(20 Suppl): 6209s-6212s.
Oral bisphosphonates as adjuvant therapy for operable breast
Prevention of breast cancer using SERMs. In: Berstein L, Santen
cancer. Clinical Cancer Research 2006; 12(20 Suppl):6301s-6304s.
R, eds. Innovative Endocrinology of Cancer. New York: Landes
Bioscience/Springer Science, 2008: 232-237.
Jean-Yves Pierga, Jorge S Reis-Filho, Susan J Cleator, Tim Dexter,
Alan MacKay, Peter Simpson, Kerry Fenwick, Marjan Iravani, Janine
Salter, Margaret Hills, Chris Jones, Alan Ashworth, Ian E Smith,
The Vogel Article Reviewed: Addressing Concerns About Breast
Cancer Prevention. Oncology 2008; 22(6): 679-682.
Microarray-based comparative genomic hybridization (aCGH) of breast cancer patients receiving neoadjuvant chemotherapy.
British Journal of Cancer 2006; Advance on-line publication
Reid, D., Doughty, J., Eastell, R., Heys, S., Howell, A., McCloskey, E.,
28.11.06; doi: 10.1038/sj.bjc.6603483 www.bjcancer.com.
Powles, T., Selby, P. & Coleman, R. (2008).
Guidance for the management of breast cancer treatment-induced
bone loss: A consensus position statement from a UK Expert
Group. Cancer Treatment Reviews, 34, S3-S18.
Do we have a clinically useful breast cancer risk reduction agent for healthy women? Nature Clinical Practice Oncology 2006; 3
Powles TJ. Global issues of chemoprevention in breast cancer.
In Rayter Z, editor. Current Innovations in the treatment and
prevention of breast cancer. London: Royal Society of Medicine
S Martino, J Costantino, M McNabb, J Mershon, K Bryant, T
Powles, R Secrest. The role of selective estrogen receptor modulators in the
prevention of breast cancer: comparison of theclinical trials. The
Andrea Z. LaCroix*, Trevor Powles, C. Kent Osborne, Kevin Wolter,
John R. Thompson, David D. Thompson, Craig Allred, Roisín
Armstrong, Steve R. Cummings, Richard Eastell, Kristine E. Ensrud,
Paul Goss, Andy Lee, Patrick Neven, David M. Reid, Madelyn
Trevor J Powles, Sue Ashley, Alwynne Tidy, Ian E Smith, Mitch
Curto, Slobodan Vukicevic, on behalf of the PEARL Investigators.
Breast Cancer Incidence in the PEARL Trial of Lasofoxifene in
Twenty-year Follow-up of the Royal Marsden Randomized,
Postmenopausal Osteoporotic Women. JNCI, 2010; 102: 1706-
Double-Blinded Tamoxifen Breast Cancer Prevention Trial. J Natl
Eugene McCloskey, MD, FRCP, Alexander Paterson, BSc, MB, ChB,
MD, John Kanis, MD, FRCP, Rita Tähtelä, Trevor Powles, CBE, PhD,
Effect of oral clodronate on bone mass, bone turnover, and
subsequent metastases in women with primary breast cancer.
EJC, 2010; 46(3): 558-565.
Trevor Powles1, Susan Diem2, Larry Wickerham3, David Cox4, Messan Amewou-Atisso4, Donato Agnusdei4, David Muram4, Bruce Mitlak4, Steven Cummings5 Effects of Arzoxifene on Breast Cancer incidence in Postmenopausal Women with Osteoporosis or with Low Bone Mass (Abs) St Antonio Breast Cancer Symposium, 2009.
Steven R. Cummings, Michael McClung, Jean-Yves Reginster, David Cox, Bruce Mitlak, John Stock, Messan Amewou-Atisso, Trevor Powles, Paul Miller, J Zanchetta, Claus Christiansen. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Mineral Research 2010, July 23, epub.
Cummings S, Ensrud K, Delmas P, LaCroix A, Vukicevic S, Reid D, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong R, Thompson D, Powles T, Zanchetta J, Kendler D, Neven P. & Eastell R. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med, 2010; 362: 686-696.
Trevor Powles. Prevention of breast cancer by newer SERMs and the future (Abs). 6th International Conference on Clinical Cancer Prevention, St Gallen 2010. Eur J Cancer 2010; 8 (2): 6 (S19).
Trevor J. Powles, Susan J. Diem, Carol J Fabian, Patrick Neven, D Lawrence Wickerham, David A Cox, David Muram, Donato Agnusdei, Sherie A. Dowsett, Messan Amewou-Atisso, Steven R. Cummings. Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. Breast Cancer Res Treat. 2012 Apr 8.
Report Effective 10-01-2013 (Standard Drug List Reflects Removals) This report highlights all changes (additions and deletions) to the CVS Caremark Performance Drug List. ADDITIONS: Therapeutic Category/ Subcategory Indication Alternatives/Comments Brand Agents: Flovent Diskus To provide an additional inhaled corticosteroid therapy option for patients four
Special section : Obstetrics & Gynaecology - Long term consequences ofSPECIAL SECTION: OBSTETRICS & GYNAECOLOGYGovernment Medical Col ege, Alappuzha, Kerala, IndiaCorrespondence to: email@example.comPolycystic Ovary Syndrome (PCOS) is emerging as a common problem among adolescents today. Its immediate problems range from oligomenorrhoea, hirsutism, acne, seborrhea and obe